Cargando…

Basal cell carcinoma: 10-year experience with electrochemotherapy

BACKGROUND: Electrochemotherapy (ECT), by combining manageable cytotoxic agents with short electric pulses, represents an effective palliative skin-directed therapy. The accumulated evidence indicates that ECT stands out as a safe and well-tolerated alternative treatment for patients with multiple o...

Descripción completa

Detalles Bibliográficos
Autores principales: Campana, Luca G., Marconato, Roberto, Valpione, Sara, Galuppo, Sara, Alaibac, Mauro, Rossi, Carlo R., Mocellin, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452531/
https://www.ncbi.nlm.nih.gov/pubmed/28569161
http://dx.doi.org/10.1186/s12967-017-1225-5
_version_ 1783240451427401728
author Campana, Luca G.
Marconato, Roberto
Valpione, Sara
Galuppo, Sara
Alaibac, Mauro
Rossi, Carlo R.
Mocellin, Simone
author_facet Campana, Luca G.
Marconato, Roberto
Valpione, Sara
Galuppo, Sara
Alaibac, Mauro
Rossi, Carlo R.
Mocellin, Simone
author_sort Campana, Luca G.
collection PubMed
description BACKGROUND: Electrochemotherapy (ECT), by combining manageable cytotoxic agents with short electric pulses, represents an effective palliative skin-directed therapy. The accumulated evidence indicates that ECT stands out as a safe and well-tolerated alternative treatment for patients with multiple or large basal cell carcinoma (BCC), who are not suitable for conventional treatments. However, long-term data and shared indications are lacking. METHODS: In this observational study, we retrospectively analyzed 84 prospectively collected patients with multiple, recurrent or locally advanced BCC who were not candidate for standard therapies and received bleomycin-based ECT according to the European Standard Operative Procedures of ECT, from 2006 to 2016. RESULTS: Disease extent was local, locally advanced and metastatic in 40 (48%), 41 (49%) and 3 (3%), respectively. Forty-four (52%) individuals had multiple BCCs. Grade 3 skin toxicity after ECT was observed in 6% of cases. Clearance rate was 50% (95% CI 39–61%). Primary presentation (p = 0.004), tumor size <3 cm (p < 0.001), well-defined borders (p = 0.021), absence of tumor ulceration (p = 0.001), non-aggressive BCC histology (p = 0.046) and age ≤69 years were associated with higher complete response rate. In patients with local BCC, the clearance rate was 72.5 and 85% after one or two ECT cycles, respectively. In the laBCC group, 32 patients (78%) achieved an objective response. Five-year recurrence rate for local and laBCC was 20 and 38%, respectively (p ≤ 0.001). CONCLUSIONS: One or two ECT cycles with bleomycin may be a valuable palliative treatment in well-selected patients with multiple BCCs and favorable tumor features. Validation of predictive factors will be imperative to match patients with optimal ECT treatment modalities. Management of laBCC with ECT warrants further investigation. Trial registration ISRCTN14633165 Registered 24 March 2017 (retrospectively registered) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1225-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5452531
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54525312017-06-02 Basal cell carcinoma: 10-year experience with electrochemotherapy Campana, Luca G. Marconato, Roberto Valpione, Sara Galuppo, Sara Alaibac, Mauro Rossi, Carlo R. Mocellin, Simone J Transl Med Research BACKGROUND: Electrochemotherapy (ECT), by combining manageable cytotoxic agents with short electric pulses, represents an effective palliative skin-directed therapy. The accumulated evidence indicates that ECT stands out as a safe and well-tolerated alternative treatment for patients with multiple or large basal cell carcinoma (BCC), who are not suitable for conventional treatments. However, long-term data and shared indications are lacking. METHODS: In this observational study, we retrospectively analyzed 84 prospectively collected patients with multiple, recurrent or locally advanced BCC who were not candidate for standard therapies and received bleomycin-based ECT according to the European Standard Operative Procedures of ECT, from 2006 to 2016. RESULTS: Disease extent was local, locally advanced and metastatic in 40 (48%), 41 (49%) and 3 (3%), respectively. Forty-four (52%) individuals had multiple BCCs. Grade 3 skin toxicity after ECT was observed in 6% of cases. Clearance rate was 50% (95% CI 39–61%). Primary presentation (p = 0.004), tumor size <3 cm (p < 0.001), well-defined borders (p = 0.021), absence of tumor ulceration (p = 0.001), non-aggressive BCC histology (p = 0.046) and age ≤69 years were associated with higher complete response rate. In patients with local BCC, the clearance rate was 72.5 and 85% after one or two ECT cycles, respectively. In the laBCC group, 32 patients (78%) achieved an objective response. Five-year recurrence rate for local and laBCC was 20 and 38%, respectively (p ≤ 0.001). CONCLUSIONS: One or two ECT cycles with bleomycin may be a valuable palliative treatment in well-selected patients with multiple BCCs and favorable tumor features. Validation of predictive factors will be imperative to match patients with optimal ECT treatment modalities. Management of laBCC with ECT warrants further investigation. Trial registration ISRCTN14633165 Registered 24 March 2017 (retrospectively registered) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-017-1225-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-31 /pmc/articles/PMC5452531/ /pubmed/28569161 http://dx.doi.org/10.1186/s12967-017-1225-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Campana, Luca G.
Marconato, Roberto
Valpione, Sara
Galuppo, Sara
Alaibac, Mauro
Rossi, Carlo R.
Mocellin, Simone
Basal cell carcinoma: 10-year experience with electrochemotherapy
title Basal cell carcinoma: 10-year experience with electrochemotherapy
title_full Basal cell carcinoma: 10-year experience with electrochemotherapy
title_fullStr Basal cell carcinoma: 10-year experience with electrochemotherapy
title_full_unstemmed Basal cell carcinoma: 10-year experience with electrochemotherapy
title_short Basal cell carcinoma: 10-year experience with electrochemotherapy
title_sort basal cell carcinoma: 10-year experience with electrochemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452531/
https://www.ncbi.nlm.nih.gov/pubmed/28569161
http://dx.doi.org/10.1186/s12967-017-1225-5
work_keys_str_mv AT campanalucag basalcellcarcinoma10yearexperiencewithelectrochemotherapy
AT marconatoroberto basalcellcarcinoma10yearexperiencewithelectrochemotherapy
AT valpionesara basalcellcarcinoma10yearexperiencewithelectrochemotherapy
AT galupposara basalcellcarcinoma10yearexperiencewithelectrochemotherapy
AT alaibacmauro basalcellcarcinoma10yearexperiencewithelectrochemotherapy
AT rossicarlor basalcellcarcinoma10yearexperiencewithelectrochemotherapy
AT mocellinsimone basalcellcarcinoma10yearexperiencewithelectrochemotherapy